gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
electroCore (Nasdaq: ECOR) announced promising results from a peer-reviewed study published in Frontiers in Neurology demonstrating the effectiveness of their gammaCore® non-invasive vagus nerve stimulation (nVNS) device in treating mild traumatic brain injury (mTBI) symptoms.
The study, involving 102 patients, showed significant improvements across multiple symptom categories when gammaCore was used as an adjunctive treatment. 34% of patients reported meaningful improvement in at least half of their persistent symptoms, with benefits observed regardless of time since injury. The treatment showed effectiveness in 16 out of 22 symptom categories, including post-traumatic headache, dizziness, and depression, with no device-related adverse events reported.
electroCore (Nasdaq: ECOR) ha annunciato risultati promettenti da uno studio sottoposto a revisione paritaria pubblicato su Frontiers in Neurology, che dimostra l'efficacia del loro dispositivo gammaCore® stimolazione vagale non invasiva (nVNS) nel trattamento dei sintomi della lesione cerebrale traumatica lieve (mTBI).
Lo studio, che ha coinvolto 102 pazienti, ha evidenziato miglioramenti significativi in diverse categorie di sintomi quando gammaCore è stato utilizzato come trattamento adiuvante. 34% dei pazienti ha riportato un miglioramento significativo in almeno la metà dei sintomi persistenti, con benefici osservati indipendentemente dal tempo trascorso dall'infortunio. Il trattamento ha mostrato efficacia in 16 su 22 categorie di sintomi, tra cui emicrania post-traumatica, vertigini e depressione, senza eventi avversi legati al dispositivo.
electroCore (Nasdaq: ECOR) anunció resultados prometedores de un estudio revisado por pares publicado en Frontiers in Neurology, que demuestra la eficacia de su dispositivo gammaCore® estimulación vagal no invasiva (nVNS) para tratar los síntomas de la lesión cerebral traumática leve (mTBI).
El estudio, que involucró a 102 pacientes, mostró mejoras significativas en varias categorías de síntomas cuando gammaCore se usó como tratamiento adyuvante. 34% de los pacientes reportaron una mejora significativa en al menos la mitad de sus síntomas persistentes, con beneficios observados independientemente del tiempo desde la lesión. El tratamiento mostró eficacia en 16 de 22 categorías de síntomas, incluyendo dolor de cabeza postraumático, mareos y depresión, sin eventos adversos relacionados con el dispositivo.
electroCore (Nasdaq: ECOR)은 Frontiers in Neurology에 게재된 동료 검토 연구에서 gammaCore® 비침습적 미주 신경 자극(nVNS) 기기가 경두개 손상 후 경미한 증상(mTBI) 치료에 효과적임을 보여주는 결과를 발표했습니다.
102명의 환자가 참여한 이 연구는 보조 치료로 gammaCore를 사용할 때 여러 증상 범주에서 유의미한 개선을 보였다고 합니다. 환자의 34%가 지속적 증상의 절반 이상에서 의미 있는 개선을 보고했으며, 손상 이후 시간에 관계없이 이익이 관찰되었습니다. 치료는 22개 증상 범주 중 16개에서 효과를 보였으며, 외상 후 두통, 현기증, 우울증 등을 포함하고 기기 관련 부작용은 보고되지 않았습니다.
electroCore ( Nasdaq : ECOR) a annoncé des résultats prometteurs d'une étude évaluée par les pairs publiée dans Frontiers in Neurology, démontrant l'efficacité de leur dispositif gammaCore® stimulation vagale non invasive (nVNS) dans le traitement des symptômes de blessure cérébrale traumatique légère (mTBI).
L'étude, qui a impliqué 102 patients, a montré des améliorations significatives dans plusieurs catégories de symptômes lorsque gammaCore était utilisé comme traitement adjuvant. 34 % des patients ont signalé une amélioration significative d'au moins la moitié de leurs symptômes persistants, avec des bénéfices observés indépendamment du délai écoulé depuis la blessure. Le traitement a montré son efficacité dans 16 sur 22 catégories de symptômes, y compris les céphalées post-traumatiques, les vertiges et la dépression, sans événements indésirables liés au dispositif.
electroCore (Nasdaq: ECOR) hat vielversprechende Ergebnisse einer von Experten begutachteten Studie angekündigt, die in Frontiers in Neurology veröffentlicht wurde und die Wirksamkeit ihres gammaCore®-Nicht-Invasiv-vagalen-Stimulationsgeräts (nVNS) bei der Behandlung von Symptomen einer leichten traumatischen Hirnverletzung (mTBI) demonstriert. Die Studie mit 102 Patienten zeigte signifikante Verbesserungen in mehreren Symptomkategorien, wenn gammaCore als unterstützende Behandlung verwendet wurde. 34% der Patienten berichteten über eine deutliche Verbesserung in mindestens der Hälfte ihrer persistierenden Symptome, mit Vorteilen unabhängig von der Zeit seit der Verletzung. Die Behandlung zeigte in 16 von 22 Symptomkategorien Wirksamkeit, einschließlich posttraumatischer Kopfschmerzen, Schwindel und Depression, ohne gerätebezogene Nebenwirkungen.
أعلنت شركة electroCore (بورصة ناسداك: ECOR) عن نتائج واعدة من دراسة مُراجعة من قِبل الأقران ونُشرت في Frontiers in Neurology تُبيّن فاعلية جهاز gammaCore® للتحفيز العصبى المبهم غير الجهازي (nVNS) في علاج أعراض إصابة الدماغ الرضحية الخفيفة (mTBI).
شارك في الدراسة 102 مريض، وأظهرت تحسنات كبيرة عبر فئات عديدة من الأعراض عندما استخدم gammaCore كعلاج مساعد. أبلغ 34% من المرضى عن تحسن معنوي في الأقل نصف الأعراض المستمرة، مع فائدة لوحظت بغض النظر عن الوقت منذ الإصابة. أظهر العلاج فاعلية في 16 من 22 فئة من الأعراض، بما في ذلك الصداع ما بعد الصدمة، الدوار، والاكتئاب، دون وقوع حوادث جانبية مرتبطة بالجهاز.
electroCore（纳斯达克：ECOR）宣布来自同行评审的 Frontiers in Neurology 发表的一项研究显示其 gammaCore® 非侵入性迷走神经刺激（nVNS）装置在治疗轻度创伤性脑损伤（mTBI）症状方面的有效性。
该研究涉及 102 名患者，结果显示将 gammaCore 作为辅助治疗时，在多个症状类别中均有显著改善。34% 的患者在持续症状中至少一半的症状上有显著改善，且随伤后时间的延长并不影响获益。治疗在 22 个症状类别中有 16 个表现出有效性，包括创伤后头痛、眩晕和抑郁等，且未报告与设备相关的不良事件。
- Significant improvement demonstrated in 16 of 22 symptom categories
- 34% of patients showed meaningful improvement in at least half of their symptoms
- Treatment effective regardless of time since injury (both recent and year-old cases)
- No device-related adverse events reported
- Addresses large market with 2.5 million annual ER visits for traumatic brain injury in US
- Study was observational rather than a controlled clinical trial
- Only 34% of patients showed meaningful improvement in half their symptoms
Insights
Positive clinical data for electroCore's gammaCore device shows promise for expanding into the untapped mTBI market with significant addressable population.
The publication of this peer-reviewed study represents a significant development for electroCore's non-invasive vagus nerve stimulation (nVNS) device, gammaCore. The data demonstrates efficacy in reducing persistent symptoms of mild traumatic brain injury (mTBI), a condition affecting 2.5 million emergency department visits annually in the US alone.
What makes these findings particularly noteworthy is the current lack of effective interventions for mTBI beyond supportive care. The study's results showing improvements across 16 of 22 symptom categories suggests gammaCore could potentially address a substantial unmet medical need. The 34% response rate with meaningful improvement in at least half of persistent symptoms represents a clinically significant outcome.
From a clinical perspective, the observation that benefits occurred regardless of time since injury is particularly valuable, as it expands the potential patient population to include both recent cases and long-term sufferers. The favorable safety profile with no device-related adverse events reported further strengthens the clinical case.
This evidence could potentially support expanded reimbursement coverage and adoption among neurologists, pain specialists, and military healthcare providers. With 1-2% of U.S. service members experiencing mTBI annually, the military market alone represents a substantial opportunity for electroCore beyond its current indications for cluster headache and migraine.
ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI).
“The CDC reports approximately 2.5 million emergency department visits each year in the United States for traumatic brain injury, with 70–
The article, entitled “Non-invasive vagus nerve stimulation is associated with the reduction in persistent post-concussion symptoms: an observational study,” found that adjunctive use of gammaCore with standard care was associated with significant and clinically meaningful improvements across multiple domains of the Neurobehavioral Symptom Inventory (NSI).
- The study included 102 patients with persistent symptoms following mTBI.
- Patients experienced significant reductions in 16 of 22 symptom categories, including post-traumatic headache, dizziness, difficulty concentrating, and depression.
- Approximately
34% of patients reported meaningful improvement in at least half of their persistent symptoms.
Importantly, improvements were observed both in patients treated within three months of injury and in those whose symptoms had persisted for over a year, suggesting that nVNS may be beneficial regardless of time since injury. No device-related adverse events were reported.
“This is the first relatively large, prospective study showing that non-invasive vagus nerve stimulation in conjunction with standard of care may improve multiple persistent symptoms of traumatic brain injury,” said Michael Ament, MD, principal investigator and lead author of the study.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Forward-Looking Statements
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about the anticipated results from the publication demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI) and improvements in persistent post-concussion symptoms, the Company’s future business strategies, growth opportunities, prospects, product development, and market expansion, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to use strategic partnerships to provide more accessibility to those looking to purchase our consumer devices, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize its products, electroCore’s results of operations and financial performance, inflation and currency fluctuations, and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
What were the key findings of electroCore's gammaCore study for traumatic brain injury?
How many patients were included in electroCore's (ECOR) gammaCore brain injury study?
What symptoms did gammaCore help improve in traumatic brain injury patients?
Were there any side effects reported in electroCore's gammaCore brain injury study?
What is the market potential for electroCore's gammaCore in treating brain injuries?
